Customize Consent Preferences

We use cookies to help you navigate efficiently and perform certain functions. You will find detailed information about all cookies under each consent category below.

The cookies that are categorized as "Necessary" are stored on your browser as they are essential for enabling the basic functionalities of the site. ... 

Always Active

Necessary cookies are required to enable the basic features of this site, such as providing secure log-in or adjusting your consent preferences. These cookies do not store any personally identifiable data.

No cookies to display.

Functional cookies help perform certain functionalities like sharing the content of the website on social media platforms, collecting feedback, and other third-party features.

No cookies to display.

Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics such as the number of visitors, bounce rate, traffic source, etc.

No cookies to display.

Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.

No cookies to display.

Advertisement cookies are used to provide visitors with customized advertisements based on the pages you visited previously and to analyze the effectiveness of the ad campaigns.

No cookies to display.

Thursday, May 29, 2025
19.7 C
London

Roche to Invest $50 Billion in U.S., Create Over 12,000 Jobs Amid Tariff Concerns

Swiss pharmaceutical giant Roche has announced plans to invest $50 billion in the United States over the next five years, a move expected to create more than 12,000 new jobs across the country. The announcement comes as major drugmakers respond to growing trade tensions and looming tariff threats under the Trump administration.

The investment will significantly expand Roche’s U.S. operations, which currently employ 25,000 people across 24 sites. According to the company, approximately 6,500 of the new roles will be in construction, while around 1,000 will support new and expanded facilities.

Roche’s plans include upgrades to manufacturing and distribution centers in Kentucky, Indiana, New Jersey, and California. The company will also build a new gene therapy manufacturing facility in Pennsylvania, a continuous glucose monitoring plant in Indiana, and a new site dedicated to producing weight loss medications—though the location for the latter has yet to be disclosed.

Additionally, a new research center focusing on cardiovascular, renal, and metabolic conditions will be established in Massachusetts.

Chief Executive Thomas Schinecker emphasized that the investment reflects Roche’s long-term commitment to the U.S. market. “Our investments of $50 billion over the next five years will lay the foundation for our next era of innovation and growth, benefiting patients in the U.S. and around the world,” he said in a statement.

The expansion is expected to shift Roche’s trade balance, with the company stating it will begin exporting more medicines from the U.S. than it imports once the new capacity is fully operational.

While Schinecker did not directly address the U.S. government’s tariff strategy, the timing of the announcement aligns with increased scrutiny of pharmaceutical imports. The Trump administration recently launched a probe into the industry, raising the possibility of a 31% tariff on Swiss pharmaceutical exports. According to United Nations trade data, pharmaceutical imports into the U.S. reached $213 billion last year, nearly triple the figure from 2014.

Roche joins other global pharmaceutical firms increasing their U.S. presence amid these developments. Earlier this month, fellow Swiss company Novartis unveiled a $23 billion U.S. investment plan, while American drugmakers Eli Lilly and Johnson & Johnson have also announced significant expansions.

The wave of investment highlights the industry’s effort to safeguard supply chains and strengthen domestic production as the U.S. administration seeks to promote onshore manufacturing through trade policy reforms.

Hot this week

Dublin Airport Braces for Record-Breaking Bank Holiday Travel Surge

 Dublin Airport is preparing for one of its busiest...

US Court Blocks Trump’s Broad Tariff Plan, Citing Abuse of Emergency Powers

A federal court has delivered a major blow to...

Carelon to Shut Down Limerick Operations, 300 Jobs to Go

Health technology company Carelon Global Solutions Ireland has announced...

Concerns Raised Over AI Use in Jobseeker Services at INOU Conference

Campaigners have urged caution over the growing use of...

Average Weekly Earnings in Ireland Top €1,000 for First Time, CSO Reports

Average weekly earnings in Ireland have risen above €1,000...

Topics

Dublin Airport Braces for Record-Breaking Bank Holiday Travel Surge

 Dublin Airport is preparing for one of its busiest...

Carelon to Shut Down Limerick Operations, 300 Jobs to Go

Health technology company Carelon Global Solutions Ireland has announced...

Concerns Raised Over AI Use in Jobseeker Services at INOU Conference

Campaigners have urged caution over the growing use of...

Average Weekly Earnings in Ireland Top €1,000 for First Time, CSO Reports

Average weekly earnings in Ireland have risen above €1,000...

Markets Mixed as U.S. Delays Tariffs on EU Goods, Retail Investors Drive Stock Surge

Global financial markets showed mixed performance this morning following...

Von der Leyen and Trump Agree to Fast-Track EU-US Trade Talks Amid Tariff Threat

The European Commission has confirmed that European Commission President...

Stripe Named New Title Sponsor of Young Scientist & Technology Exhibition

Financial technology giant Stripe has been announced as the...

Related Articles

Popular Categories